Program
Doxorubicin
Also written as “doxorubicin hydrochloride”, “Doxorubicin hydrochloride (liposomal)” and “doxorubicin”.
Its studies are mostly in Breast Neoplasms · Sarcoma · Lymphoma, Large B-Cell, Diffuse · Carcinoma, Hepatocellular · Sarcoma, Kaposi, led by 16 companies.
Drug pageDoxorubicin: every studyMany companies study it; this page follows only the 34 they lead. All 779 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 50 open or running | phase 2since Jan 25, 2005 | Jan 25, 2005 | none ahead |
| Johnson & Johnsonits history only | 40 open or running | phase 3since Feb 9, 2005 | Jan 31, 2005 | none ahead |
| Sanofiits history only | 40 open or running | phase 3since Jul 11, 2001 | Jul 11, 2001 | none ahead |
| Sequus Pharmaceuticalsits history only | 40 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Amgenits history only | 30 open or running | phase 3since Mar 31, 2003 | Jul 5, 2000 | none ahead |
| InSightecits history only | 22 open or running | phase 2since Nov 7, 2022 | Nov 7, 2022 | none ahead |
| Philogenits history only | 20 open or running | phase 2since May 25, 2010 | May 25, 2010 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 2since Oct 24, 2005 | Oct 24, 2005 | none ahead |
| Alfacellits history only | 10 open or running | phase 3since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Bio-Cancer Treatment Internationalits history only | 10 open or running | phase 1since Sep 30, 2009 | Sep 30, 2009 | none ahead |
| Presage Biosciencesits history only | 10 open or running | phase 1since Jan 22, 2017 | Jan 22, 2017 | none ahead |
| Sopherion Therapeuticsits history only | 10 open or running | phase 3since Feb 17, 2006 | Feb 17, 2006 | none ahead |
| Spirovant Sciencesits history only | 11 open or running | phase 2since Jul 18, 2024 | Jul 18, 2024 | Dec 31, 2026phase 2 · NCT06526923 |
| Sutphin Drugsits history only | 10 open or running | early phase 1since Jun 3, 2019 | Jun 3, 2019 | none ahead |
| Valerio Therapeuticsits history only | 10 open or running | phase 3since Jul 26, 2012 | Jul 26, 2012 | none ahead |
| Zivenaits history only | 10 open or running | phase 2since May 11, 2004 | May 11, 2004 | none ahead |
Also a collaborator on its studies: AbbVie and PharmaMar.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Nov 1, 1999.
- Aug 16, 2006Phase 2 study in Breast NeoplasmsSanofi · NCT00365365 · 214 enrolled · United States
- Apr 17, 2007Phase 2 study in Carcinoma, DuctalSanofi · NCT00461344 · 20 enrolled
- Sep 30, 2009Bio-Cancer Treatment International’s first study: phase 1 study in NeoplasmsNew to Bio-Cancer Treatment InternationalBio-Cancer Treatment International · NCT00988195 · 15 enrolled · Hong Kong
- May 25, 2010Philogen’s first study: phase 2 study in Breast NeoplasmsNew to PhilogenPhilogen · NCT01131364 · 29 enrolled · Italy
- Jul 26, 2012Valerio Therapeutics’ first study: phase 3 study in Carcinoma, HepatocellularNew to Valerio TherapeuticsValerio Therapeutics · NCT01655693 · 397 enrolled · United States, Austria, Belgium and more
- Mar 14, 2013Phase 1 study in NeoplasmsJohnson & Johnson · NCT01815294 · 54 enrolled · United States, Belgium, Spain and more
- Feb 24, 2014Phase 1 study in SarcomaPhilogen · NCT02076620 · 29 enrolled · Germany, Italy
- Jan 29, 2016Phase 1 study in Neoplasm MetastasisEli Lilly · NCT02677116 · 68 enrolled · United States, Japan
- May 24, 2016Phase 1 study in SarcomaEli Lilly · NCT02783599 · 51 enrolled · United States, France, Italy and more
- Jan 22, 2017Presage Biosciences’ first study: phase 1 study in SarcomaNew to Presage BiosciencesPresage Biosciences · NCT03056599 · 23 enrolled · United States
- Sep 13, 2017Phase 1 study in SarcomaEli Lilly · NCT03283696 · 24 enrolled · United States, Germany, Italy
- Jun 3, 2019Sutphin Drugs’ first study: early phase 1 study in Lymphoma LeukemiaNew to Sutphin DrugsSutphin Drugs · NCT03975205 · 500 enrolled · India
- Nov 7, 2022InSightec’s first studies: 2 phase 2 studies in Brain NeoplasmsNew to InSightecInSightec · NCT05615623, NCT05630209
- Jul 18, 2024Spirovant Sciences’ first study: phase 2 study in Cystic FibrosisNew to Spirovant SciencesSpirovant Sciences · NCT06526923 · 15 planned · United States
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Cystic FibrosisSpirovant Sciences · NCT06526923
TargetBeta
“DNA topoisomerase II alpha inhibitor; DNA inhibitor”ChEMBL 37, by rule
Other programs on TOP2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Etoposiderule | Hoffmann-La Roche | phase 3 | 28 |
| amrubicinrule | Bristol-Myers Squibb | phase 3 | 9 |
| Daunorubicinrule | kura-oncology-inc | phase 3 | 7 |
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06526923Cystic Fibrosis · United States | 2 | Recruiting | Spirovant Sciences | Dec 31, 2026 | 15 |
| NCT05630209Brain Neoplasms · United States | 2 | Active, not recruiting | InSightec | Jun 2026 | 10 |
| NCT05615623Brain Neoplasms · Canada | 2 | Active, not recruiting | InSightec | Jun 2026 | 10 |
| NCT03975205Lymphoma Leukemia · India | Early 1 | UNKNOWN | Sutphin Drugs | Oct 31, 2019 | 500 |
| NCT03283696Sarcoma · United States, Germany, Italy | 1 | Completed | Eli Lilly | Apr 29, 2019 | 24 |
| NCT03056599Sarcoma · United States | 1 | Completed | Presage Biosciences | Jul 22, 2021 | 23 |
| NCT02783599Sarcoma · United States, France, Italy and more | 1 | Completed | Eli Lilly | Jul 5, 2018 | 51 |
| NCT02677116Neoplasm Metastasis · United States, Japan | 1 | Completed | Eli Lilly | Oct 10, 2018 | 68 |
| NCT02076620Sarcoma · Germany, Italy | 1 | Completed | Philogen | Jan 25, 2018 | 29 |
| NCT01815294Neoplasms · United States, Belgium, Spain and more | 1 | Completed | Johnson & Johnson | Dec 2014 | 54 |
| NCT01655693Carcinoma, Hepatocellular · United States, Austria, Belgium and more | 3 | Completed | Valerio Therapeutics | May 2017 | 397 |
| NCT01131364Breast Neoplasms · Italy | 2 | Terminated | Philogen | Mar 2012 | 29 |
| NCT00988195Neoplasms · Hong Kong | 1 | Completed | Bio-Cancer Treatment International | Aug 2009 | 15 |
| NCT00461344Carcinoma, Ductal | 2 | Terminated | Sanofi | Jun 2005 | 20 |
| NCT00365365Breast Neoplasms · United States | 2 | Completed | Sanofi | Oct 2011 | 214 |
| NCT00312208Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Oct 2008 | 3,299 |
| NCT00294996Breast Neoplasms · United States, Argentina, Canada and more | 3 | UNKNOWN | Sopherion Therapeutics | 363 | |
| NCT00250874Breast Neoplasms · Italy | 2 | UNKNOWN | Teva Pharmaceutical Industries | 45 | |
| NCT00244127Aggressive Non-Hodgkin's Lymphoma in the Elderly. · France, Germany, Italy and more | 2 | UNKNOWN | Teva Pharmaceutical Industries | 75 | |
| NCT00216645Ovarian Neoplasms | 2 | Completed | Johnson & Johnson | 74 | |
| NCT00191789Breast Neoplasms · India | 2 | Completed | Eli Lilly | Apr 2009 | 65 |
| NCT00115414Breast Neoplasms | 2 | Completed | Amgen | ||
| NCT00103506Multiple Myeloma · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | May 2014 | 646 |
| NCT00102609Sarcoma | 1 | Completed | Johnson & Johnson | 41 | |
| NCT00102219Breast Neoplasms · Brazil, Greece, Hungary and more | 2 | Completed | Eli Lilly | 77 | |
| NCT00082472Neoplasm Metastasis · United States | 2 | UNKNOWN | Zivena | 30 | |
| NCT00057382Carcinoma, Hepatocellular · United States, Brazil, China and more | 3 | Terminated | Amgen | 750 | |
| NCT00021255Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Sanofi | Dec 2014 | 3,222 |
| NCT00005960Pain · United States | 2 | UNKNOWN | Amgen | ||
| NCT00002319Sarcoma, Kaposi · United States | 3 | Completed | Sequus Pharmaceuticals | ||
| NCT00002318Sarcoma, Kaposi · United States | 3 | UNKNOWN | Sequus Pharmaceuticals | 225 | |
| NCT00002147Sarcoma, Kaposi · United States | 3 | Completed | Sequus Pharmaceuticals | ||
| NCT00002105Sarcoma, Kaposi · United States | 3 | Completed | Sequus Pharmaceuticals | 220 | |
| NCT00003034Mesothelioma, Malignant · United States, Germany, Italy and more | 3 | UNKNOWN | Alfacell | Feb 2008 | 300 |
How it is read
Names in the registry
- “Doxorubicin”, 29 entries
- “doxorubicin hydrochloride”, 6 entries
- “Doxorubicin hydrochloride (liposomal)”, 4 entries
- “doxorubicin”, 3 entries
- “CHOP”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 15 studies
- Sarcoma, 8 studies
- Lymphoma, Large B-Cell, Diffuse, 5 studies
- Carcinoma, Hepatocellular, 4 studies
- Sarcoma, Kaposi, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.